Kodiak Sciences (KOD) EPS (Weighted Average and Diluted) (2020 - 2026)
Kodiak Sciences (KOD) reported EPS (Weighted Average and Diluted) of -$0.94 for Q1 2026, up 13.76% on a YoY basis from -$0.83 in Q1 2025, and up 9.62% quarter-over-quarter from -$1.04 in Q4 2025.
Kodiak Sciences (KOD) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Kodiak Sciences has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.94 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 13.76% year-over-year to -$0.94; the trailing twelve-month figure through Mar 2026 stood at -$4.17 (down 14.88% YoY), and the FY2025 full-year result was -$4.32, down 28.96% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.94, up from -$1.04 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.82 in Q1 2024, with the low at -$1.83 in Q1 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$1.17 across 5 years, with a median of -$1.09 in 2025.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) tumbled 61.11% — and 2024, when it soared 43.79%.
- Kodiak Sciences' EPS (Weighted Average and Diluted) stood at -$1.35 in 2022, then increased by 16.3% to -$1.13 in 2023, then grew by 25.66% to -$0.84 in 2024, then slipped by 23.81% to -$1.04 in 2025, then climbed by 9.62% to -$0.94 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.94 (Q1 2026), -$1.04 (Q4 2025), and -$1.16 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Kodiak Sciences | 1.92 Bn | 1.92 Bn | - | -0.94 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.94 |
| Dec 31, 2025 | -1.04 |
| Sep 30, 2025 | -1.16 |
| Jun 30, 2025 | -1.03 |
| Mar 31, 2025 | -1.09 |
| Dec 31, 2024 | -0.84 |
| Sep 30, 2024 | -0.84 |
| Jun 30, 2024 | -0.86 |
| Mar 31, 2024 | -0.82 |
| Dec 31, 2023 | -1.13 |
| Sep 30, 2023 | -0.95 |
| Jun 30, 2023 | -1.53 |
| Mar 31, 2023 | -1.35 |
| Dec 31, 2022 | -1.35 |
| Sep 30, 2022 | -1.47 |
| Jun 30, 2022 | -1.74 |
| Mar 31, 2022 | -1.83 |
| Dec 31, 2021 | -1.80 |
| Sep 30, 2021 | -1.30 |
| Jun 30, 2021 | -1.08 |